Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 19;10:17618. doi: 10.1038/s41598-020-74634-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Histopathological evaluation of specimens from artificial psoriatic human skin and imiquimod-induced psoriatic rat skin: (A) Epidermal thickness at day 7 post-treatment in the artificial psoriatic (i–v) and rat psoriatic (xi, x) skins stained with hematoxylin and eosin (magnification, × 400). (i, vi) non-treatment; (ii, vii) extraction; (iii, viii) betamethasone; (iv, ix) calcitriol (D3); (v, x) normal skin groups. Bar graphs comparing the epidermal thickness in the artificial psoriatic (xi) and rat psoriatic (xii) skins. (B) Anatomical and histopathological appearances in imiquimod-induced psoriasis rats; gross skin lesion after induction with 62.5 mg of imiquimod from day 0 to day 7 (i–viii). Histopathological changes in rat psoriatic skin after 7 days of induction (ix–xiii). Ix, normal epidermis; x, acanthosis; xi, dermatitis; xii, folliculitis; xiii, hyperkeratosis. (xiv, xv) Line graph comparing the psoriatic area and severity index from day 0 to day 7 post-induction in each group (xiv). Bar graph comparing the histopathological scores among each treatment group (xv).